SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-19-003649
Filing Date
2019-06-14
Accepted
2019-06-14 16:23:42
Documents
5
Period of Report
2019-07-31
Effectiveness Date
2019-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2239045zdef14a.htm DEF 14A 411182
2 G50439.JPG g50439.jpg GRAPHIC 22116
3 G761950.JPG g761950.jpg GRAPHIC 7584
4 G114982BCI001.GIF g114982bci001.gif GRAPHIC 127069
5 G114982BCI002.GIF g114982bci002.gif GRAPHIC 92094
  Complete submission text file 0001047469-19-003649.txt   755497
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 19899216
SIC: 2834 Pharmaceutical Preparations